yuytu6ygt56j1hg5145646468468341l kmnlikh;ouhg

gfdgfdgfdgfdgfdgfdgfbvnfvjnfh

Senior cardiologists and biomedical data scientists have unveiled a novel deep learning framework capable of identifying sub-clinical arrhythmias hours before overt manifestations. In a multi-centre trial involving over 15,000 ECG streams across Tamil Nadu, the system maintained a 99.2% accuracy threshold without false positives.

Participants consuming whole fermented foods demonstrated sustained colonization of 19 beneficial bacterial strains and marked reduction in 16 circulating inflammatory cytokines.

Athletic medicine specialists recommend dedicating 70-80% of weekly training volume to Zone-2 intensity, which protects cardiac microvasculature while minimizing chronic joint wear.

Neuroscientists demonstrate that conscious extension of the exhalation phase stimulates parasympathetic vagal tone, triggering rapid reduction in systemic inflammatory markers.

Pediatricians recommend establishing digital-free bedtime routines and morning natural light exposure to synchronize circadian rhythms and enhance classroom attention spans.

The advisory links chronic antenatal iron depletion with neurochemical fatigue and heightened susceptibility to perinatal mood disorders, highlighting proactive micronutrient optimization.

Metabolic specialists advocate for personalized chrononutrition and post-meal ambulatory walks, which cut blood glucose excursions by upwards of 34% across monitored cohort groups.

The landmark 10-year observational study tracked over 25,000 asymptomatic individuals aged 35 to 55, confirming that subclinical vascular inflammation accelerates plaque calcification years before overt symptoms emerge.

Researchers have validated an innovative liquid biopsy assay capable of identifying trace tumor biomarkers up to 18 months prior to radiographic visibility on standard CT or MRI screenings.

The American Gut Project showed individuals consuming 30+ plant types per week had significantly higher levels of short-chain fatty acid producing bacteria.

Nitric oxide relaxes smooth vascular muscle tissue, supporting normal blood pressure ranges and optimal coronary microcirculation.

Prolonged exhalation shifts autonomic tone toward heart rate deceleration, down-regulating amygdala reactivity during high-stress episodes.

Periodic postural changes activate muscle GLUT4 glucose transporters and prevent arterial stiffness associated with uninterrupted prolonged sitting.

Dietary protein stimulates peptide YY and GLP-1 satiety hormones, while viscous fiber slows gastric emptying for sustained focus and metabolic health.

Clinical research shows morning photons stimulate retinal ganglion cells, synchronizing cortisol rhythm and enhancing deep slow-wave sleep cycles.

Discover how 12 flowing poses can transform your morning routine and overall health.

Overview

Sun Salutation Secrets: Elevate Your Wellness with Surya Namaskar provides evidence-based techniques to improve daily wellness, optimize lifestyle habits, and sustain peak long-term health.

Getty Images ROCHESTER, Minn. — Mayo Clinic researchers have found that artificial intelligence (AI)-enabled spatial analysis can identify patterns in routine pathology slides that may help clinicians identify which patients with pancreatic cancer are at greater risk of recurrence after treatment and surgery.

The study, published in Clinical Cancer Research, suggests that looking at how residual cancer is organized — not just how much remains — could eventually improve estimates of recurrence risk, particularly for patients whose tumors show only a limited response to chemotherapy before surgery. Patients with a more fragmented, intermixed pattern of cancer and the surrounding tissue, or stroma, had earlier recurrence.

The amount of residual cancer alone did not reliably separate patients at higher and lower risk. D. "Current pathology assessments largely tell us how much tumor is left after treatment. D. , a Mayo Clinic oncologist and senior author of the study. Dr. Carr and his team used an AI tool to identify cancer and stromal regions on standard pathology slides, then measured how those regions formed patches, boundaries and mixed areas to evaluate spatial patterns tied to a higher risk of recurrence.

Reading the geography of cancer The study analyzed tissue from 203 patients with pancreatic ductal adenocarcinoma who received treatment before surgery but showed only a limited pathologic response. The researchers combined an AI-enabled digital pathology platform with methods adapted from landscape ecology to analyze standard hematoxylin and eosin, or H&E, slides. The approach measured tissue shape, fragmentation, and the degree to which the cancer and stroma were intermixed.

The work builds on Dr. Carr's broader research applying ecological principles to cancer. His team uses machine learning and spatial analysis to map the pancreatic cancer ecosystem and study how cancer cells interact with neighboring cells and tissues — relationships that may influence treatment resistance and recurrence. AI overlay of pancreatic cancer tissue showing cancer glands in purple and surrounding scar-like stroma in yellow, with the fragmented pattern measured in the study.

Two spatial signatures predicted disease-free survival even after accounting for stage, lymph node status, and other established clinical and pathologic risk factors. In one model, high-risk patients had a 71% higher adjusted risk of recurrence. In another, high-risk patients had more than twice the adjusted risk. These spatial models helped distinguish patients at higher and lower risk when standard measures, including how much cancer remained, did not.

Because the approach uses pathology slides already generated as part of routine care, it could potentially give clinicians additional information to inform recurrence risk without requiring another tissue test. Linking tumor patterns and immune response "What is exciting is that this information is already present in the tissue," Dr. Carr says.

" The research also found that high-risk spatial patterns contained fewer immune cells within the cancer itself, with immune cells tending to collect around the tumor instead of entering it. The finding underscores the importance of the tumor microenvironment — the cells and tissues surrounding a tumor — in treatment resistance and disease behavior.

More broadly, the work aligns with Mayo Clinic's Precure Research priority to use data and technology to predict risk earlier and create opportunities to intercept serious disease before it advances. "Our long-term goal is to better identify which patients remain at greatest risk and ultimately use that knowledge to guide more individualized surveillance, adjuvant therapy and clinical trial design," Dr. Carr says.

The researchers say the results are promising but need to be confirmed in prospective studies before this approach could be used to inform clinical decision-making. The research was supported in part by the Gerstner Family Foundation Career Development Award, the Grand Forks Career Development Award, the Mayo Clinic Center for Clinical and Translational Science, and the ARPA-H ADAPT program. For a complete list of authors, disclosures and funding, review the study .

### About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. edu The post AI-enabled analysis of pathology slides may help assess risk of pancreatic cancer recurrence appeared first on Mayo Clinic News Network .

ROCHESTER, Minn. — Mayo Clinic researchers have identified a potential new approach to treating glioblastoma that could help the immune system fight the aggressive brain cancer while improving the effectiveness of existing chemotherapy. The preclinical research , published in Nature Communications, found that inhibiting the enzymatic activity of a protein called MALT1 can reprogram immune cells surrounding glioblastomas, shifting them from a state that helps protect the cancer to one that promotes an antitumor immune response.

Researchers also found that treatment with a MALT1 inhibitor slowed tumor growth in preclinical models and that combining MALT1 with temozolomide, the chemotherapy most commonly used to treat glioblastoma, enhanced temozolomide effectiveness. In one preclinical model, median survival substantially increased when this chemotherapy was combined with MALT1 inhibition in comparison to treatment with temozolomide alone. D.

"Glioblastoma is extraordinarily difficult to treat, in part because the tumor is able to manipulate the immune cells around it and create an environment that protects the cancer. D. , lead author and researcher in the Department of Laboratory Medicine and Pathology at Mayo Clinic. Glioblastoma is the most common and aggressive primary cancerous brain tumor in adults and accounts for roughly 5% of malignant brain tumors in children.

Despite surgery, radiation and chemotherapy, the cancer remains incurable and almost always returns. The findings raise the possibility of a future approach that could help patients get more benefit from existing treatments. D. D. D. , vice chair for research in the Department of Laboratory Medicine and Pathology at Mayo Clinic. D.

More research is needed to determine which specific subtypes of glioblastoma may be most likely to respond to MALT1-targeted therapy and to evaluate its potential for use in patients. Review the study for a complete list of authors, disclosures and funding. ### About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing.

Visit the Mayo Clinic News Network for additional Mayo Clinic news. edu The post Mayo Clinic researchers find a way to reprogram immune cells and boost chemotherapy response in glioblastoma appeared first on Mayo Clinic News Network .

Multiple myeloma is the second-most common blood cancer, and the risk is higher among men, Black Americans and people with a family history of the disease. While multiple myeloma is not considered curable, advances in treatment may offer better prognoses. Dr. Sikander Ailawadhi , a Mayo Clinic hematologist and oncologist , explains how new therapies and ongoing research are changing the outlook for people with the disease.

Watch: The Mayo Clinic Minute Journalists: Broadcast-quality video (1:10) is in the downloads at the end of this post. " Read the script . Multiple myeloma is a cancer that forms in a type of blood cell called a plasma cell that builds up in bone marrow. "When plasma cells multiply and crowd up the bone marrow, they can produce certain abnormal proteins," says Dr. Ailawadhi. Damage caused by multiple myeloma can lead to anemia, weakened bones, frequent infections and kidney failure.

"Treatment for multiple myeloma has come a long way," Dr. Ailawadhi says. " This includes bone marrow transplantation , novel immunotherapy agents and chimeric antigen receptor-T cell therapy , also known as CAR-T cell therapy. Dr. Ailawadhi says research is ongoing to better predict who may be at risk for multiple myeloma and to develop new treatments. "We are able to see the field advancing rapidly and how major treatment advances are progressing to benefit patients," says Dr. Ailawadhi.

" The post Mayo Clinic Minute: New approaches bring progress in treating multiple myeloma (VIDEO) appeared first on Mayo Clinic News Network .

DEAR MAYO CLINIC: I've heard that many symptoms of gynecologic cancers can mimic menstrual or menopausal changes, such as bleeding and pelvic pain. What symptoms should never be ignored, and when do I know it's time to see a healthcare professional? ANSWER: Pay attention to changes that are new, persistent, worsening or simply different from what is typical for your body.

Many gynecologic cancer symptoms also can have noncancerous causes, but certain changes deserve medical evaluation rather than automatically considering them a natural part of menstruation, menopause or another common condition. There are five types of gynecologic cancers: ovarian , endometrial , cervical , vulvar and vaginal .

Their warning signs can overlap with expected changes across a woman's life, which is why the pattern of a symptom — whether it's new, persistent or progressing — matters. Symptoms that should prompt a conversation with a healthcare professional include: Postmenopausal bleeding. Menopause means going 12 months without a menstrual period. Any bleeding after that point should be evaluated. Bleeding after intercourse.

Cancer isn't the only possible cause, but bleeding after intercourse should be checked. Pelvic pain that's new or getting worse. If you usually have discomfort with menstrual periods but notice that the pain is becoming progressively worse, that change deserves attention. Persistent bloating or feeling full quickly. Feeling full soon after starting to eat is called early satiety. Bloating and early satiety can occur with ovarian cancer, particularly when symptoms are new or worsening.

Changes in bowel or bladder habits. When changes develop or get worse, they should be looked into rather than considered only as a gastrointestinal or urinary condition. New or persistent vulvar changes. A new lump or lesion, bleeding, itching, burning or irritation on your vulva should be examined. A biopsy may be recommended, particularly if symptoms persist or don't improve with treatment. The key is to know your own baseline.

A symptom doesn't have to be severe, but if it's unusual for you or continues, it should be evaluated. One common misconception is that a Pap test means a woman has been screened for all gynecologic cancers. A Pap test only screens for cervical cancer and cervical precancer. It doesn't screen for ovarian, endometrial, vulvar or vaginal cancers. For cancers without routine screening tests, recognizing symptoms and seeking diagnostic evaluation if you become concerned is especially important.

Screening and diagnostic evaluation are different. Screening is performed in people who don't have symptoms. Diagnostic evaluation, such as imaging or a biopsy, is prompted by a symptom or other concern, and it may involve additional testing depending on each person's situation. Risk of gynecological cancers differs by cancer type, but several factors may be important: Aging puts people at greater risk of these cancers. Obesity is a risk factor for a common type of endometrial cancer.

Inherited conditions, including BRCA1 and 2 and Lynch syndrome, can increase the risk of certain ovarian or endometrial cancers. Family history of cancers, such as breast, ovarian or colon cancer, can be important when assessing inherited risk. Human papillomavirus, or HPV, is associated with cervical and vulvar cancer risk. Smoking can make it more difficult to clear up an HPV infection, increasing the chance that it will persist.

Knowing your family history and discussing relevant risk factors with a healthcare professional can help guide appropriate care. Earlier detection can reduce the challenges of treatment and may improve outcomes. In some cases, cancer found earlier may be treated with surgery without the need for additional treatments like chemotherapy or radiation therapy. For some younger patients, earlier diagnosis also may allow them to consider fertility-preserving treatment options.

The goal isn't to assume that every episode of bleeding, pelvic pain or bloating means cancer. It's to recognize when a change deserves an explanation. If something is new, persistent, worsening or simply doesn't feel right for your body, have it evaluated. You know your body best, and speaking up when something feels different is an important part of protecting your health. D.

, Obstetrics & Gynecology, Mayo Clinic, Rochester, Minnesota The post Mayo Clinic Q&A: Warning signs of gynecologic cancer every woman should know appeared first on Mayo Clinic News Network .

Brenda and her husband, John, on vacation in Alaska in August 2026. Fainting became commonplace for Brenda in 2021. She and her husband, John, were so accustomed to what they called "blood pressure crashes" that they developed a routine. "I would feel dizzy, nauseated and sweaty, and (I would) alert my husband. He would run for a bucket and a cold compress. I would lie on the ground and get my feet up," Brenda shares. John would check her blood pressure.

Once she stabilized, they would go about their day. Brenda, then 53, attributed the episodes to traveling too much for work or not drinking enough water, especially because many occurred on hot days in her home state of Arkansas. "I had an excuse every time," she says. But in 2023, as she headed out for a run with John — her favorite leisure activity — Brenda fainted and couldn't get back up. John called an ambulance. Watch: Dr.

Guru Kowlgi explain cardioneural ablation Journalists: Broadcast-quality sound bites are available in the downloads at the end of the post. /Cardiovascular Medicine/Mayo Clinic. After extensive testing at the hospital and a review of Brenda's smartwatch health data, her physician found that the fainting episodes coincided with drops in her heart rate.

Brenda received a pacemaker , a device implanted under the skin that sends small electrical impulses to the heart to keep it from beating too slowly or pausing too long. But the fainting episodes continued. Brenda also experienced fatigue, brain fog, hair loss and inflammation throughout her body. "I'd gone from a person with great energy and vitality to someone who struggled to walk. I was trying every remedy possible," Brenda says.

She tried cold plunges, gluten-free and dairy-free diets, and intermittent fasting. She took 13 different medications and multiple vitamins, and she stopped air travel. Nothing worked. She lived in constant fear that something was seriously wrong with her heart. Brenda continued checkups with her local care team. Despite her symptoms, she kept receiving the same report: "Your heart is fine. Your pacemaker is working.

" In April 2025, before Brenda left to visit her home country of Ireland, a nurse practitioner who had been part of her care team from the beginning expressed concern about Brenda's condition and advised her to seek care elsewhere. The nurse practitioner referred Brenda to Mayo Clinic , and soon afterward, Brenda and John made the 10-hour drive to Rochester, Minnesota. S. , a cardiologist and cardiac electrophysiologist.

She walked into the appointment with little hope, expecting him to deliver the same message she had heard from other physicians: "You're fine. " Instead, Dr. " "I couldn't believe it. John and I felt relieved to finally have answers," Brenda says. Brenda was diagnosed with vasovagal syncope , a common condition that causes fainting when the vagus nerve triggers a drop in heart rate and blood pressure.

"A pacemaker is usually the last treatment option for patients like Brenda, but it does not solve all their issues," says Dr. Kowlgi. Pacemakers treat slow heart rates, which are the result of vasovagal syncope, but do not address the root cause. Thus, Dr. Kowlgi says patients may continue to have lightheadedness, and even faint, and the condition can significantly affect quality of life. For Brenda, Dr.

Kowlgi recommended a specialized procedure called cardioneuroablation, also referred to as cardioneural ablation. The procedure uses a catheter to target and ablate, or destroy, areas around the nerve cells in the heart that contribute to the abnormal reflex. "It is like a recalibration," explains Dr. Kowlgi. " Brenda skiing with her family in Minnesota in December 2025. Using cardioneuroablation to target the cause Dr.

Kowlgi first performed cardioneuroablation at Mayo Clinic in 2022 and has helped advance its use for vasovagal syncope. Cardioneuroablation builds on techniques used in cardiac ablation procedures to treat heart rhythm disorders. Dr. Kowlgi is among the physicians using the approach to treat vasovagal syncope, including in patients with pacemakers, such as Brenda. In 2024, Dr. Kowlgi performed cardioneuroablation for the first time on a patient with an existing pacemaker.

"We started building on that experience. " Brenda underwent the procedure in October 2025. "When I came off the operating table, I could feel my energy coming back. I was out walking within a week," Brenda says. Within two months of the procedure, Brenda went from having her pacemaker provide pacing 40% of the time to no pacing, and her symptoms resolved. She spent Christmas in Rochester, skiing with her family for the first time in years. In February 2026, Brenda's pacemaker was removed.

The cardioneuroablation procedure allowed Brenda to return to running. Returning to running, traveling and family life As Dr. Kowlgi continues clinical research on cardioneuroablation and its potential uses, Brenda and John are reclaiming their life together. "I thought I'd never be able to run another marathon or plan travel with John to see my mum in Ireland, our sons in New York and Kentucky, and visit the last state on our bucket list," Brenda says.

"Now I run 3 to 4 miles a day and am about to go on a cruise to Alaska. " The post Innovative heart procedure helps woman reclaim her active life (VIDEO) appeared first on Mayo Clinic News Network .

DEAR MAYO CLINIC: I recently read that Mayo Clinic researchers discovered DNA changes linked to Alzheimer's disease. Does this mean scientists are getting closer to preventing or curing Alzheimer's disease? ANSWER: Research advances are helping scientists better understand Alzheimer's disease , but no single study has found a cure or identified a single cause.

Instead, studies like the one discovering DNA changes linked to Alzheimer’s provide important clues that may help guide future treatments. Alzheimer's disease is the most common cause of dementia. It affects memory, thinking, behavior and the ability to carry out everyday activities. More than 7 million Americans are living with Alzheimer's disease, and that number is expected to grow as the population ages.

Scientists know that age is the greatest risk factor for Alzheimer's disease, but aging alone doesn't explain why some people develop the condition while others do not. Genetics, lifestyle factors and environmental influences also appear to play a role. Researchers are working to understand how these factors interact in the brain. For many years, Alzheimer's research has focused on two proteins found in the brain: amyloid and tau.

The buildup of these proteins is one of the best-known features of the disease. While these proteins remain important, researchers now recognize that Alzheimer's is a complex disease involving many biological processes beyond amyloid and tau. A recent Mayo Clinic study explored another piece of the puzzle: changes in how the brain turns genes on and off. Genes are sections of DNA that provide instructions for how cells work.

Cells can control which genes are active and which remain inactive, allowing them to carry out different functions without changing the underlying DNA sequence. Scientists call this process epigenetics. These chemical changes can influence how cells behave and respond to aging, disease and environmental factors. In the study, researchers examined brain tissue from hundreds of people with Alzheimer's disease and looked for patterns in these gene-regulating changes.

They identified several changes strongly linked to the tau protein. The research also highlighted the possible importance of oligodendrocytes — brain cells that support nerve cells by producing myelin, a protective layer that helps signals move efficiently. When myelin is damaged, communication in the brain may be disrupted.

The findings suggest that Alzheimer's disease may involve not only damage to nerve cells but also changes in the systems that support how those cells communicate with one another. This growing understanding is encouraging researchers to look beyond traditional explanations of the disease. So, what does this mean for patients today? These findings are not expected to change how Alzheimer's disease is diagnosed or treated right now.

Scientists must confirm the findings, better understand how these changes affect the brain and determine whether the discoveries can lead to safe and effective treatments. One reason researchers are excited about epigenetics is that, unlike inherited DNA changes, some gene-control changes may be reversible. While much more research is needed, the findings so far suggest that future therapies could target these biological processes.

Studies like this also help identify new areas for investigation and may reveal why Alzheimer's disease affects people differently. As researchers learn more, they move closer to developing more personalized approaches to prevention and treatment. The Mayo Clinic team that did research on the DNA changes associated with the disease also created a free online tool that allows researchers worldwide to explore the study's data.

Called the Multiomic Atlas of AD Brain Endophenotypes , the searchable resource lets scientists look up specific genes and view results in interactive tables and graphs. By making these findings widely available, researchers hope to accelerate discoveries and support the development of improved treatments for Alzheimer's disease and other neurological conditions. There's still no cure for Alzheimer's disease, but researchers continue to make progress.

Each discovery helps them better understand the disease and brings them closer to finding ways to prevent, slow or treat it. D. , chair, Department of Neuroscience, Mayo Clinic; Department of Neurology, Mayo Clinic, Jacksonville, Florida The post Mayo Clinic Q&A: What do DNA changes in Alzheimer's disease mean for patients and families? appeared first on Mayo Clinic News Network .

Getty Images ROCHESTER, Minn. — Mayo Clinic Platform today announced that its Accelerate program for healthcare technology companies is now available through a multiyear engagement pathway. The inaugural participants of the multiyear track include 12 companies developing artificial intelligence (AI)-powered solutions to enhance care delivery and healthcare operations.

" The multiyear pathway is designed for select companies seeking sustained access to Mayo Clinic Platform's discovery environment, data, technology and expertise. Through an extended engagement, participants can work alongside Mayo Clinic Platform's experts and leverage its de-identified clinical data ecosystem to advance the development and validation of their digital health solutions.

The 12 companies selected as the first participants in the multiyear pathway are developing AI-enabled solutions that leverage clinical data and advanced analytics to transform healthcare. Cappsule is an AI-enabled ambient monitoring platform designed to support clinical decision-making through continuous, real-world data capture.

CerebraAI develops AI-powered software as a medical device that aims to upgrade the diagnostic capability of noncontrast computed tomography imaging, bringing it closer to MRI standards. Clair Health is building a women's health intelligence platform grounded in continuous, direct hormone data. Durotimi AI is a pioneering healthcare technology company dedicated to transforming cancer care through advanced, localized AI.

Electrokare is building AI infrastructure for continuous biological intelligence — turning today's snapshot healthcare system into continuous measurement. Floe Health is a clinical reasoning engine for hospital case management. Koroid is an AI-native operating system for healthcare operations. MedLink Global is pioneering AI-powered solutions to transform psychiatric care. OPTT Health is a clinically led AI platform for scalable mental healthcare.

PONS aims to make ultrasound accessible to the mass market by addressing the limitations of high-resolution images in the early stages of disease. Radical Health offers a patient-facing second opinion service that allows patients to receive personalized treatment recommendations. Respiree is an AI/machine learning health tech company building state-of-the-art, clinically-validated AI for managing disease progression across healthcare's care continuum.

Since its launch in 2022, Accelerate has supported more than 130 companies from around the world. To learn more about the program or to apply for an upcoming cohort, visit Mayo Clinic Platform Accelerate . ### About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic Platform Mayo Clinic Platform is a strategic initiative of Mayo Clinic that enables collaboration, data-driven innovation and responsible AI development to transform healthcare globally. Mayo Clinic Platform is reimagining healthcare as an ecosystem — one where data, digital solutions and expertise flow seamlessly between innovators and care teams to improve care for patients everywhere.

edu The post Mayo Clinic Platform Accelerate announces inaugural participants of its new multiyear pathway program appeared first on Mayo Clinic News Network .

ROCHESTER, Minn. — Mayo Clinic researchers tested an approach that uses artificial intelligence (AI) to help people without previous ultrasound experience capture heart images and identify patients who may have a common and serious heart valve condition.

In a study published in JAMA Cardiology and presented at the 2026 ESC Congress, after four hours of training, novice users were able to collect focused heart ultrasound images while using AI models to guide their image collection and help to analyze the images for signs of moderate or greater aortic stenosis . Aortic stenosis happens when the heart's aortic valve narrows, making it harder for the heart to pump blood to the rest of the body.

It affects approximately 7% of people age 75 and older and is the most common reason for heart valve intervention worldwide. People with aortic stenosis may not experience symptoms until the condition is more advanced. Finding the disease earlier can help ensure patients receive appropriate monitoring and care. "A comprehensive echocardiogram is the standard diagnostic test for aortic stenosis.

However, its use is resource-intensive, requiring specialized equipment as well as trained personnel with expertise in both image acquisition and interpretation. D. , a cardiologist at Mayo Clinic and senior author of the study. D. , a Mayo Clinic cardiologist who co-led the study. First, the researchers developed and validated the deep learning algorithm using echocardiograms from patients at Mayo Clinic sites in Arizona, Florida, the Mayo Clinic Health System and Rochester.

They evaluated the model's performance on hand-held ultrasound images collected by experienced sonographers. In the prospective study, nine research staff members with no previous clinical or ultrasound experience used AI guidance to perform focused heart ultrasounds after four hours of training. The staff members were able to use the AI model to analyze nearly 97% of the exams.

It helped the researchers correctly identify 93% of patients with moderate or more severe aortic stenosis and correctly rule out 96% of patients who did not have the condition. About 10% of exams were flagged for review by a heart imaging specialist. The combined approach of AI plus human review reduced false-positive results, but it also meant that some patients with aortic stenosis were not identified. Dr. Tsaban and Dr.

Bird note that the approach is intended to help people screen for aortic stenosis and determine who may benefit from additional testing. It is not intended to replace a comprehensive echocardiogram or a physician's evaluation. Patients identified as potentially having moderate or more severe aortic stenosis still need comprehensive echocardiography to confirm the diagnosis and determine the severity of the condition.

The findings suggest that putting AI tools in the hands of people with limited ultrasound experience could help more patients access screening for aortic stenosis, particularly in communities where comprehensive echocardiography and trained imaging professionals are less readily available. " Mayo Clinic has a financial interest in the technology referenced in this news release and will use any revenue it receives to support its nonprofit mission in patient care, education and research.

### About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. edu The post AI-assisted approach helps novice users capture heart ultrasound images, identify aortic stenosis appeared first on Mayo Clinic News Network .

ROCHESTER, Minn. — A liver disease affecting nearly 30% of adults worldwide is not a single illness but five biologically distinct subtypes, Mayo Clinic researchers have found. Each carries different risks for heart disease, liver failure, cancer and the need for liver transplantation.

The study, published in Nature Communications and conducted in collaboration with scientists at Virginia Tech, shows that metabolic dysfunction-associated steatotic liver disease has multiple pathways — some tied to obesity and diabetes, others driven by inherited genetic factors. Notably, genetic subtypes are associated with a higher risk of progression to advanced liver disease, including in patients without typical metabolic risk factors.

The findings could help identify high-risk patients earlier and guide more precise screening and personalized treatment. D. , co-senior author and a bioinformatician at Mayo Clinic. " Metabolic dysfunction-associated steatotic liver disease, formerly called nonalcoholic fatty liver disease, occurs when fat builds up in the liver. It often develops without symptoms but can progress to inflammation, scarring and irreversible damage.

It is a leading cause of cirrhosis, liver cancer and transplantation worldwide. This illustration shows the changes that can occur as liver disease advances. Getty Images. Decoding liver disease at scale To uncover these subtypes, researchers integrated genetic sequencing with detailed clinical data from more than 4,600 patients with the disease.

The dataset spanned a wide range of measures — from liver enzymes, body mass index and lipid levels to coexisting conditions such as diabetes, depression and sleep apnea. Using advanced computational modeling, the team identified groups of patients who shared underlying biological signals, defining distinct subtypes of the disease. D. , co-senior author and the Everett J. and Jane M. Hauck Midwest Associate Director of Research and Innovation.

" The discovery was powered by Mayo Clinic's Research Data Atlas, a platform that connects genetic data with patient records to reveal patterns across large populations — a system Dr. Klee helped build. A key component of the Atlas is the Tapestry Study , which has generated Mayo Clinic's largest collection of exome data from more than 100,000 participants. The dataset captures key genetic information that shapes how diseases develop and progress. D.

, the Carlson and Nelson Endowed Executive Director for the Center for Individualized Medicine who led the Tapestry Study and is a co-author of the research. " Liver disease's hidden effects across the body The study also revealed links beyond the liver. For the first time, researchers found that specific subtypes are associated with conditions such as depression, sleep apnea and migraine, underscoring the disease's broad systemic impact across multiple organ systems.

Next, the team plans to test the approach in broader patient populations and explore how these subtypes respond to different treatments, including therapies such as GLP-1 receptor agonists. D. student at Virginia Tech, contributed to the research while at Mayo Clinic. For a complete list of authors, disclosures and funding, review the study .

### About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. edu The post 5 subtypes of common liver disease discovered — including rapidly progressing genetic forms appeared first on Mayo Clinic News Network .

ROCHESTER, Minn. — BioLabs Rochester, MN is building momentum toward its September opening, with leadership in place and recruitment underway for early-stage biotechnology and health technology companies seeking to grow alongside Mayo Clinic and Minnesota's expanding life science ecosystem.

Announced in 2025 and developed through a collaboration among stakeholders Mayo Clinic, BioLabs, Destination Medical Center (DMC) and Mortenson Properties, BioLabs Rochester, MN reflects a shared vision to strengthen the region's innovation ecosystem and support the growth of life science companies in Minnesota. With construction nearing completion and leadership in place, recruitment is now underway for the incubator's inaugural resident companies.

Located in Two Discovery Square at Discovery Square Innovation District, the newly constructed 17,000-square-foot shared laboratory and office facility will support emerging biotechnology and health technology companies developing new diagnostics, therapeutics, medical devices and digital health technologies while advancing the partners' shared vision to grow Rochester as a destination for life science innovation.

, will serve as BioLabs site director, leading facility operations, startup scaling support and innovation network development. Schicklberger joins BioLabs Rochester, MN from the University of Minnesota, where she served as chief operations officer and founder of the Minnesota Bioinnovation Accelerator. She previously held business development and operations roles at startups in biotech, automation and SaaS/diagnostics.

, will serve as Mayo Clinic's director of startup engagement, helping connect BioLabs Rochester, MN resident companies with Mayo Clinic physicians, scientists and business development teams to explore research, clinical and commercialization opportunities. Hannigan brings experience in pharmaceutical research and startup acceleration, including leading the Merck Digital Sciences Studio in Boston before joining Mayo Clinic.

"Rochester offers a unique combination of world-class clinical expertise, a growing innovation ecosystem and a strong commitment to advancing healthcare," says Johannes Fruehauf, CEO of BioLabs. "As we prepare to open our doors, we're excited to establish BioLabs' first Midwest location in a community where entrepreneurs can work alongside leading researchers, clinicians and industry partners.

" Application process open Applications are now being accepted for early-stage biotechnology and health technology companies interested in joining the inaugural BioLabs Rochester, MN community. Companies selected for the incubator will have access to flexible, turnkey laboratory and office space, entrepreneurial programming, and opportunities to collaborate with Mayo Clinic while becoming part of the growing community of innovators and companies at Discovery Square Innovation District.

"BioLabs Rochester represents a significant investment in the people and companies that will shape the future of health," says Patrick Seeb, DMC executive director. "We are grateful to BioLabs, Mayo Clinic and Mortenson for the partnership and confidence required to bring the first BioLabs location in the Midwest to Discovery Square Innovation District. To entrepreneurs developing the next breakthrough in health, our message is simple: This place was built for you.

" Resident companies will also have access to BioLabs' national network of investors, industry partners and entrepreneurial resources, along with pathways to engage Mayo Clinic expertise through scientific, clinical and commercial collaborations and ecosystem support through Destination Medical Center.

"Innovation happens when great ideas have the opportunity to be tested, refined and translated into solutions that improve patient care," says Andrew Danielsen, chief business development officer, Mayo Clinic. " Learn more about BioLabs Rochester, MN and the application process here . ### About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing.

Visit the Mayo Clinic News Network for additional Mayo Clinic news. About BioLabs BioLabs is a global innovation infrastructure company creating the physical and community backbone that powers life science discovery worldwide. Through a growing network of premium shared laboratories and coworking spaces, BioLabs provides turnkey access to state-of-the-art research facilities, entrepreneurial programming, and deep industry and capital connections.

These integrated ecosystems enable innovators from early-stage founders to established R&D teams to rapidly translate ideas into impact without the constraints of traditional lab ownership. The BioLabs network now spans major innovation hubs across the United States, Europe, and Asia, serving as a catalyst for collaboration and a launchpad for breakthroughs that advance human health and sustainability.

About Destination Medical Center Destination Medical Center (DMC) is the largest public-private economic initiative in Minnesota's history. The 20-year plan to transform Rochester into a global destination for health and wellness will attract developers, investors, startups and entrepreneurs to live, work and play in America's City for Health. mn. edu The post BioLabs Rochester MN opens, building momentum with startup recruitment appeared first on Mayo Clinic News Network .